Biomarkers

Share:
ResearchersAgainstAlzheimer's would like to thank Roche Diagnostics for their support of this project.
Return to the full list of Biomarkers

Plasma putative biomarkers (i.e. Ab40 amyloid and total Ab42 amyloid, free, bound, free/bound, truncated, sAPPα) (BALTAZAR)

Method of Measurement (Pre-analytical Tools)
Blood/Plasma
Biomarker Measured
Amyloid
Use
Diagnostic
Prognostic
Predictive
Stage of Development
Clinical trials
Active vs Completed Trials
Active
Aim/Results

Examine diagnostic performance and predictive and prognostic values of new plasma markers of AD. Specifically, the main objective of the study is to examine the association between plasma free Aβ peptide concentration and (1) the risk of conversion of subjects with Mild Cognitive Impairment (MCI) into Alzheimer's disease (AD) and (2) the risk of worsening of the disease in patients with mild and moderate stages of AD.

Target Population/ Population Being Studied

People with amnestic impairment (i.e. MCI and AD)

Length of Current Trial
24 months
Number of Trial Participants

Actual enrollment: 1067; Projected enrollment: 1300 subjects with amnestic impairment (MCI, n=650 and AD, n=650)

Estimated Trial Completion
February 2019
What is Required from Patients

blood draw, mild discomfort, in clinic visits

What is Required from the Health System

phlebotomist, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g.,mass spectrometer, protein assay kit, ELISA, western blot, or qPCR)

Sponsor

Assistance Publique - Hôpitaux de Paris

“New Biomarker for Alzheimer's Disease Diagnostic (BALTAZAR).” ClinicalTrials.gov. Accessed October 10, 2019. https://clinicaltrials.gov/ct2/show/NCT01315639?term=biomarker&recrs=abdf&cond=Alzheimer+Disease&rank=1